Glaukos Corporation

NYSE:GKOS Stock Report

Market Cap: US$6.9b

Glaukos Future Growth

Future criteria checks 1/6

Glaukos is forecast to grow earnings and revenue by 56.6% and 18.8% per annum respectively. EPS is expected to grow by 58.7% per annum. Return on equity is forecast to be -11.7% in 3 years.

Key information

56.6%

Earnings growth rate

58.7%

EPS growth rate

Medical Equipment earnings growth17.5%
Revenue growth rate18.8%
Future return on equity-11.7%
Analyst coverage

Good

Last updated05 Sep 2024

Recent future growth updates

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07
Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Recent updates

Glaukos Corporation: Ripe For Some Consolidation

Sep 11

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 28
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 81% Above Its Share Price

Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Aug 07
Glaukos Corporation (NYSE:GKOS) Just Reported And Analysts Have Been Lifting Their Price Targets

Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Jul 18
Glaukos Corporation's (NYSE:GKOS) Popularity With Investors Is Clear

Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Jun 11
Glaukos (NYSE:GKOS) Is Carrying A Fair Bit Of Debt

Glaukos Stock: Still Unproven Whether A New Bull Market Has Begun

May 30

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 24
Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Apr 22
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Apr 04
Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Feb 21
Glaukos Corporation's (NYSE:GKOS) Intrinsic Value Is Potentially 69% Above Its Share Price

Is Glaukos (NYSE:GKOS) A Risky Investment?

Jan 21
Is Glaukos (NYSE:GKOS) A Risky Investment?

Glaukos: Remains A Hold Due To High Valuation And Negative Profitability

Jan 09

Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Dec 20
Glaukos Corporation's (NYSE:GKOS) 27% Jump Shows Its Popularity With Investors

Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Nov 03
Why Glaukos Corporation (NYSE:GKOS) Could Be Worth Watching

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Oct 05
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Continued Growth Rates, Regulatory Tailwinds, And Support

Sep 01

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 16

Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Apr 19
Risks To Shareholder Returns Are Elevated At These Prices For Glaukos Corporation (NYSE:GKOS)

Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Feb 19
Health Check: How Prudently Does Glaukos (NYSE:GKOS) Use Debt?

Glaukos: Trial Momentum Building, Profitability Differentials Yet To Pull Through

Feb 14

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Oct 16
Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos pays $10M upfront to license iVeena's eye disorder therapy IVMED-80

Aug 24

Glaukos: Gross Margins Compressing Despite FY22 Guidance Revision

Aug 04

Glaukos gains as Stifel upgrades to Buy citing 2022 sales upside

Jul 12

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Jun 28
Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Earnings and Revenue Growth Forecasts

NYSE:GKOS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026584-597910411
12/31/2025465-8563414
12/31/2024374-143-39-2414
6/30/2024342-159-82-71N/A
3/31/2024326-141-75-61N/A
12/31/2023315-135-78-58N/A
9/30/2023304-129-75-51N/A
6/30/2023297-126-97-70N/A
3/31/2023289-139-104-74N/A
12/31/2022283-99-63-33N/A
9/30/2022285-90-65-34N/A
6/30/2022288-56-2511N/A
3/31/2022294-28-730N/A
12/31/2021294-50-2325N/A
9/30/2021294-38-140N/A
6/30/2021284-60-1913N/A
3/31/2021238-83-29-6N/A
12/31/2020225-120-30-23N/A
9/30/2020218-73-44-38N/A
6/30/2020211-71-37-31N/A
3/31/2020238-37-19-14N/A
12/31/201923715-50N/A
9/30/2019225-191021N/A
6/30/2019211-121728N/A
3/31/2019195-121626N/A
12/31/2018181-13919N/A
9/30/2018169-141014N/A
6/30/2018165-61117N/A
3/31/2018163-4N/A17N/A
12/31/20171590N/A26N/A
9/30/2017151-1N/A17N/A
6/30/2017140-1N/A14N/A
3/31/20171275N/A16N/A
12/31/20161145N/A12N/A
9/30/20161022N/A8N/A
6/30/201691-1N/A4N/A
3/31/201680-35N/A-2N/A
12/31/201572-37N/A-2N/A
9/30/201566-40N/A-3N/A
6/30/201559-39N/A-2N/A
3/31/201552-9N/A-3N/A
12/31/201446-12N/A-7N/A
9/30/201438-11N/A-8N/A
6/30/201433-12N/A-10N/A
3/31/201426-13N/A-13N/A
12/31/201321-13N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GKOS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GKOS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GKOS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GKOS's revenue (18.8% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: GKOS's revenue (18.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GKOS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y